Cancer Susceptibility and Cancer Susceptibility Syndromes
January 29-February 1, 2014
The Westin San Diego
San Diego, CA
CONFERENCE CO-CHAIRPERSONS:
Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA
Phillip A. Dennis, Johns Hopkins University, Baltimore, MD
Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA
The study of rare human genetic cancer susceptibility syndromes has led to a broader view of cancer pathogenesis, diagnosis and treatment in the general population. The systematic study of rare cancer-prone families has elucidated a complex network of cancer proteins and tumor suppressors, many of which function in DNA repair, cell cycle checkpoint control, and telomere maintenance. For example, the Li-Fraumeni syndrome has illustrated how study of a rare familial cluster of pediatric sarcomas and breast cancer can provide a wider view of clinical genetics for both inherited and sporadic cancers. The primary focus of this AACR Special Conference will be the cooperation of cancer susceptibility proteins in tumor initiation, progression and metastasis. We will also discuss how mechanisms of control of mRNA/Protein Translation, when dysregulated, can lead to tumorigenesis. We will focus on new cancer susceptibility syndromes and how these syndromes have elucidated new cell regulatory pathways. Finally, we will consider how these syndromes have led to novel cancer diagnostic tools and chemoprevention approaches.
Program as of March 25
|
Wednesday, January 29, 2014
|
Welcome and Keynote Talks
7:30 p.m.-8:30 p.m.
Welcome and Introductions
Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA
Phillip A. Dennis, Johns Hopkins University, Baltimore, MD
Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA
Title to be announced
Bruce Ponder, Cancer Research UK, Cambridge, United Kingdom
|
Opening Reception
8:30 p.m.-10:00 p.m.
|
|
Thursday, January 30, 2014
|
Continental Breakfast
7:00 a.m.-8:00 a.m.
|
Session 1: Cancer Susceptibility
8:00 a.m.-10:00 a.m.
Genetic network analysis of cancer susceptibility
Allan Balmain, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Clonal evolution of hematopoiesis in inherited bone marrow failure syndromes
William D. Foulkes, McGill University, Montreal General Hospital, Montreal, QC, Canada
DICER1: From ontogenesis to oncogenesis
Monica Bessler, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA
Short talks from proffered papers
|
Break
10:00 a.m.-10:30 a.m.
|
Session 2: Fanconi Anemia / BRCA2
10:30 a.m.-12:30 p.m.
Title to be announced
Markus Grompe, Oregon Health & Science University, Portland, OR
Toxic aldehydes and the in-vivo function of the FA repair pathway
Ketan J. Patel, MRC Laboratory of Molecular Biology, Cambridge, United Kingdom
The BRCA1 tumor suppressor network
Roger A. Greenberg, University of Pennsylvania, Philadelphia, PA
Short talks from proffered papers
|
Lunch on Own / Free Time
12:30 p.m.-2:30 p.m.
|
Session 3: Cowden and TSC Syndromes
2:30 p.m.-4:30 p.m.
Cowden syndrome: One gene-many syndromes; one syndrome-many genes?
Charis Eng, The Cleveland Clinic, Cleveland, OH
Title to be announced
Suzanne J. Baker, St. Jude Children’s Research Hospital, Memphis, TN
Tuberous sclerosis and LAM: Targeting mTOR-dependent metabolic dependencies
Elizabeth P. Henske, Brigham and Women’s Hospital, Boston, MA
Short talks from proffered papers
|
Poster Session A / Reception
4:30 p.m.-6:30 p.m.
|
Dinner on Own / Evening Off
6:30 p.m.-
|
|
Friday, January 31, 2014
|
Continental Breakfast
7:00 a.m.-8:00 a.m.
|
Session 4: DNA Damage Response / p53 Associated Syndromes
8:00 a.m.-10:00 a.m.
Li-Fraumeni syndrome: p53 and beyond
David Malkin, University of Toronto Hospital for Sick Children, Toronto, ON, Canada
New insights into ataxia-telangiectasia
Michael B. Kastan, Duke Cancer Institute, Durham, NC
Regulation of the DNA double-strand break response by RNF168, the RIDDLE syndrome protein
Daniel Durocher, Samuel Lunenfeld Research Institute, Toronto, ON, Canada
Short talks from proffered abstracts
|
Break
10:00 a.m.-10:30 a.m.
|
Session 5: Chemoprevention
10:30 a.m.-12:30 p.m.
Risk reduction in hereditary breast cancer syndromes
Judy Garber, Dana-Farber Cancer Institute, Boston, MA
Title to be announced
Phillip A. Dennis, Johns Hopkins University, Baltimore, MD
Additional speaker to be announced
|
Poster Session B / Lunch
12:30 p.m.-3:00 p.m.
|
Session 6: Other Syndromes
3:00 p.m.-5:00 p.m.
Title to be announced
Laura J. Niedernhofer, The Scripps Research Institute, Jupiter, FL
Identification of pathways that prevent genome instability
Richard D. Kolodner, Ludwig Institute for Cancer Research, UCSD School of Medicine, La Jolla, CA
Molecular basis for cancer predisposition in Bloom's syndrome
Ian D. Hickson, University of Copenhagen, Copenhagen, Denmark
Short talks from proffered papers
|
Dinner on Own / Evening Off
5:00 p.m.-
|
|
Saturday, February 1, 2014
|
Continental Breakfast
7:00 a.m.-8:00 a.m.
|
Session 7: Aging, Telomere and Ribosome Related Syndromes
8:00 a.m.-9:30 a.m.
Dyskeratosis congenita and related syndromes
Inderjeet S. Dokal, Barts and the London School of Medicine and Dentistry, London, United Kingdom
Telomeric regulation of the mitotic checkpoint
Jan Karlseder, Salk Institute for Biological Studies, La Jolla, CA
Age-related aneuploidization in cancer, aging, and senescence
Jan M. van Deursen, Mayo Clinic, Rochester, MN
|
Break
9:30 a.m.-10:00 a.m.
|
Session 8: BRCA1
10:00 a.m.-11:30 a.m.
Role of BRCA1 in genome stability
Andre Nussenzweig, National Cancer Institute-CCR, Bethesda, MD
Double-strand break repair and tumor suppression
Maria Jasin, Memorial Sloan-Kettering Cancer Center, New York, NY
Short talks from proffered abstracts
|
Closing Remarks / Departure
11:30 a.m.-11:45 a.m.
|